Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Back Eckert, N (1 Dec 2023) 'What Is the dark side of GLP-1 receptor agonists?' Medscape Medical News
The medication arrives
YoungRLLumsdenALMartinAMSchoberGPezosNThazhathSSet al
The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI
Pol Arch Intern Med
Safety profile : Whilst lower doses might theoretically reduce the incidence of dose-dependent adverse effects such as nausea and vomiting, this has not been systematically studied, and the overall risk-benefit ratio remains unknown
